- Home
- MPB vs CRGX Comparison
MPB vs CRGX Comparison
Compare MPB & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPB
- CRGX
- Stock Information
- Founded
- MPB 1868
- CRGX 2021
- Country
- MPB United States
- CRGX United States
- Employees
- MPB N/A
- CRGX N/A
- Industry
- MPB Major Banks
- CRGX
- Sector
- MPB Finance
- CRGX
- Exchange
- MPB Nasdaq
- CRGX Nasdaq
- Market Cap
- MPB 641.4M
- CRGX 190.0M
- IPO Year
- MPB N/A
- CRGX 2023
- Fundamental
- Price
- MPB $29.94
- CRGX $4.60
- Analyst Decision
- MPB Buy
- CRGX Hold
- Analyst Count
- MPB 2
- CRGX 7
- Target Price
- MPB $36.00
- CRGX $5.33
- AVG Volume (30 Days)
- MPB 99.3K
- CRGX 1.5M
- Earning Date
- MPB 07-23-2025
- CRGX 08-11-2025
- Dividend Yield
- MPB 2.69%
- CRGX N/A
- EPS Growth
- MPB 23.94
- CRGX N/A
- EPS
- MPB 2.88
- CRGX N/A
- Revenue
- MPB $181,865,000.00
- CRGX N/A
- Revenue This Year
- MPB $24.31
- CRGX $57.81
- Revenue Next Year
- MPB $13.74
- CRGX N/A
- P/E Ratio
- MPB $10.32
- CRGX N/A
- Revenue Growth
- MPB 9.21
- CRGX N/A
- 52 Week Low
- MPB $21.16
- CRGX $3.00
- 52 Week High
- MPB $33.87
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- MPB 70.69
- CRGX 62.02
- Support Level
- MPB $29.54
- CRGX $4.32
- Resistance Level
- MPB $30.39
- CRGX $4.75
- Average True Range (ATR)
- MPB 0.61
- CRGX 0.18
- MACD
- MPB 0.28
- CRGX 0.03
- Stochastic Oscillator
- MPB 88.86
- CRGX 77.17
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.